NasdaqCM:ESTAMedical Equipment
Did Carillon’s ESTA Endorsement of Expense Discipline Quietly Recast Establishment Labs’ Path to Profitability?
Carillon Eagle Small Cap Growth Fund recently highlighted Establishment Labs Holdings in its fourth-quarter 2025 investor letter as a leading contributor, citing robust post-FDA-approval demand, strong brand recognition, and clinical advantages.
The fund also pointed to tight expense control and a path toward EBITDA profitability and cash flow positivity, underscoring growing confidence in Establishment Labs’ operational progress.
We’ll now explore how this endorsement of Establishment Labs’...